Tuesday, February 13, 2007
In Nov. 2006, StemCells, Inc. announced the first transplantation of the Company's proprietary human neural stem cell product--HuCNS-SC(TM). This transplant is the first of six that are planned as part of the Company's Phase I clinical trial designed to evaluate the safety and preliminary efficacy of HuCNS-SC as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative condition afflicting infants and children.
The above chart shows you the company stock profile for the last ten years. You can tell how risky to invest stem cell industry. Who knows when the great dream will come true? If that happened, the stem cell industry will be the another millionaire generator. Again, don't forget to check out the employment opportunities. This company has quite a few openings now! Wanna go to California? This is your chance!
Sources: MSN Money and StemCells, Inc.
Subscribe to Posts [Atom]